+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)

Congenital Hyperinsulinism - Pipeline Insight, 2022

  • PDF Icon

    Clinical Trials

  • 60 Pages
  • August 2022
  • Region: Global
  • DelveInsight
  • ID: 5174501
This Congenital Hyperinsulinism - Pipeline Insight, 2022” report provides comprehensive insights about 4+ companies and 6+ pipeline drugs in Congenital Hyperinsulinism pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Geography Covered

  • Global coverage

Congenital Hyperinsulinism Understanding

Congenital Hyperinsulinism: Overview

Pneumococcal infections are caused by Streptococcus pneumoniae, a gram-positive, catalase-negative organism commonly referred to as pneumococcus. The bacteria spread through contact with people who are ill or by healthy people who carry the bacteria in the back of their nose. Pneumococcal infections can be mild or severe. Symptoms of pneumococcal infections vary depending on the site of the infection. Most pneumococcal infections occur in the Lungs (pneumonia), Middle ear (otitis media, which is common among children), Sinuses (sinusitis) Pneumococcal infections usually fall into one of two categories: non-invasive pneumococcal infections - these occur outside the major organs or the blood and tend to be less serious and invasive pneumococcal infections - these occur inside a major organ or the blood and tend to be more serious. People with a weakened immune system are most at risk of catching a pneumococcal infection. Diagnosis is based on the physical exam and medical history. Treatment is with antibiotics and vaccines that can prevent pneumococcal infections.

"Congenital Hyperinsulinism - Pipeline Insight, 2022" report by the publisher outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Congenital Hyperinsulinism pipeline landscape is provided which includes the disease overview and Congenital Hyperinsulinism treatment guidelines. The assessment part of the report embraces, in depth Congenital Hyperinsulinism commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Congenital Hyperinsulinism collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Congenital Hyperinsulinism R&D. The therapies under development are focused on novel approaches to treat/improve Congenital Hyperinsulinism.
This segment of the Congenital Hyperinsulinism report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Congenital Hyperinsulinism Drugs

Avexitide: Eiger Bio

Avexitide is an investigational, first-in-class glucagon-like peptide-1 receptor (GLP-1r) antagonist in development for the treatment of congenital hyperinsulinism (HI) and post-bariatric hypoglycemia (PBH). Avexitide has been granted Breakthrough Therapy designation for both HI and PBH. By binding to the GLP-1r on pancreatic beta cells and preventing GLP-1r signaling, avexitide works upstream of beta cell insulin secretion to reduce dysregulated insulin secretion and the occurrence of hypoglycemia. By addressing underlying disease mechanisms, avexitide may offer a targeted approach to treating hypoglycemia in patients with hyperinsulinemic hypoglycemia, including HI and PBH. Eiger has developed a novel formulation of avexitide for subcutaneous injection.

Congenital Hyperinsulinism: Therapeutic Assessment

This segment of the report provides insights about the Congenital Hyperinsulinism drugs segregated based on following parameters that define the scope of the report, such as:

Major Players in Congenital Hyperinsulinism

There are approx. 4+ key companies which are developing the therapies for Congenital Hyperinsulinism. The companies which have their Congenital Hyperinsulinism drug candidates in the most advanced stage, i.e. Phase II include Eiger Bio.


The report covers around 6+ products under different phases of clinical development like

  • Late stage products (Phase III)
  • Mid-stage products (Phase II)
  • Early-stage product (Phase I) along with the details of
  • Pre-clinical and Discovery stage candidates
  • Discontinued & Inactive candidates
  • Route of Administration

Congenital Hyperinsulinism pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

  • Intranasal
  • Intrathecal
  • Intravenous
  • Oral
  • Oral/Intravenous
  • Parenteral
  • Subcutaneous
  • Subcutaneous/Intramuscular
  • Transdermal
  • Molecule Type

Products have been categorized under various Molecule types such as

  • Antisense oligonucleotide
  • Gene therapy
  • Hormones
  • Neuropeptides
  • Oligonucleotides
  • Small Molecule
  • Triglyceride
  • Product Type
Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

Congenital Hyperinsulinism: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Congenital Hyperinsulinism therapeutic drugs key players involved in developing key drugs.

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Congenital Hyperinsulinism drugs.

Congenital Hyperinsulinism Report Insights

  • Congenital Hyperinsulinism Pipeline Analysis
  • Therapeutic Assessment
  • Unmet Needs
  • Impact of Drugs

Congenital Hyperinsulinism Report Assessment

  • Pipeline Product Profiles
  • Therapeutic Assessment
  • Pipeline Assessment
  • Inactive drugs assessment
  • Unmet Needs

Key Questions Answered

Current Treatment Scenario and Emerging Therapies:
  • How many companies are developing Congenital Hyperinsulinism drugs?
  • How many Congenital Hyperinsulinism drugs are developed by each company?
  • How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Congenital Hyperinsulinism?
  • What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Congenital Hyperinsulinism therapeutics?
  • What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
  • What are the clinical studies going on for Congenital Hyperinsulinism and their status?
  • What are the key designations that have been granted to the emerging drugs?

Key Players

  • Eiger BioPharmaceuticals
  • Zealand Pharma
  • Hanmi Pharmaceutical
  • Crinetics Pharmaceuticals
  • AmideBio

Key Products

  • Avexitide
  • Dasiglucagon
  • HM 15136
  • CRN 04777
  • ABG 023

Table of Contents


Executive Summary

Congenital Hyperinsulinism: Overview
  • Causes
  • Mechanism of Action
  • Signs and Symptoms
  • Diagnosis
  • Disease Management
Pipeline Therapeutics
  • Comparative Analysis
Therapeutic Assessment
  • Assessment by Product Type
  • Assessment by Stage and Product Type
  • Assessment by Route of Administration
  • Assessment by Stage and Route of Administration
  • Assessment by Molecule Type
  • Assessment by Stage and Molecule Type
Congenital Hyperinsulinism- Analytical Perspective

Late Stage Products (Phase III)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Mid Stage Products (Phase II)
  • Comparative Analysis
Avexitide: Eiger BioPharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I/II)
  • Comparative Analysis
Drug name: Company name
  • Product Description
  • Research and Development
  • Product Development Activities
Early Stage Products (Phase I)
  • Comparative Analysis
CRN 04777: Crinetics Pharmaceuticals
  • Product Description
  • Research and Development
  • Product Development Activities
Preclinical Stage Products
  • Comparative Analysis
ABG 023: AmideBio
  • Product Description
  • Research and Development
  • Product Development Activities
Inactive Products
  • Comparative Analysis
Congenital Hyperinsulinism Key Companies

Congenital Hyperinsulinism Key Products

Congenital Hyperinsulinism- Unmet Needs

Congenital Hyperinsulinism- Market Drivers and Barriers

Congenital Hyperinsulinism- Future Perspectives and Conclusion

Congenital Hyperinsulinism Analyst Views

Congenital Hyperinsulinism Key Companies

AppendixList of Figures
Figure 1 Total Products for Congenital Hyperinsulinism
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products

Companies Mentioned

A selection of companies mentioned in this report includes:

  • Avexitide
  • Dasiglucagon
  • HM 15136
  • CRN 04777
  • ABG 023